Literature DB >> 27587383

Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.

Lianne E Rotin1,2, Neil MacLean1, Ahmed Aman3, Marcela Gronda1, Feng-Hsu Lin1, Rose Hurren1, XiaoMing Wang1, Jeffrey L Wrana4, Alessandro Datti4,5, Rima Al-Awar3,6, Mark D Minden1,2, Aaron D Schimmer7,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27587383      PMCID： PMC5394872          DOI： 10.3324/haematol.2016.146894

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Authors:  M Hidalgo; L L Siu; J Nemunaitis; J Rizzo; L A Hammond; C Takimoto; S G Eckhardt; A Tolcher; C D Britten; L Denis; K Ferrante; D D Von Hoff; S Silberman; E K Rowinsky
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

2.  Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.

Authors:  David W Koh; Ann M Lawler; Marc F Poitras; Masayuki Sasaki; Sigrid Wattler; Michael C Nehls; Tobias Stöger; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-10       Impact factor: 11.205

3.  Gefitinib induces myeloid differentiation of acute myeloid leukemia.

Authors:  Kimberly Stegmaier; Steven M Corsello; Kenneth N Ross; Jenny S Wong; Daniel J Deangelo; Todd R Golub
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

4.  Mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate for the termination of second trimester pregnancy: a prospective, open-label, randomized clinical trial.

Authors:  Shuping Hou; Qinfang Chen; Lanrong Zhang; Aihua Fang; Linan Cheng
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-08       Impact factor: 2.435

5.  Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.

Authors:  Christoph Weber; Thiemo B Schreiber; Henrik Daub
Journal:  J Proteomics       Date:  2011-11-15       Impact factor: 4.044

6.  A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Authors:  Sylvain Thepot; Simone Boehrer; Valérie Seegers; Thomas Prebet; Odile Beyne-Rauzy; Eric Wattel; Jacques Delaunay; Emmanuel Raffoux; Mathilde Hunault; Eric Jourdan; Fatiha Chermat; Marie Sebert; Guido Kroemer; Pierre Fenaux; Lionel Adès
Journal:  Leuk Res       Date:  2014-10-07       Impact factor: 3.156

7.  Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Authors:  Elodie Lainey; Marie Sébert; Sylvain Thépot; Marie Scoazec; Cyrielle Bouteloup; Carole Leroy; Stéphane De Botton; Lorenzo Galluzzi; Pierre Fenaux; Guido Kroemer
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

8.  Pilot study of erlotinib in patients with acute myeloid leukemia.

Authors:  Hamid Sayar; Magdalena Czader; Chirag Amin; Mary Cangany; Heiko Konig; Larry D Cripe
Journal:  Leuk Res       Date:  2014-12-02       Impact factor: 3.156

9.  Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

Authors:  Simone Boehrer; Lionel Adès; Thorsten Braun; Lorenzo Galluzzi; Jennifer Grosjean; Claire Fabre; Génèviève Le Roux; Claude Gardin; Antoine Martin; Stéphane de Botton; Pierre Fenaux; Guido Kroemer
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

10.  Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.

Authors:  Lianne E Rotin; Marcela Gronda; Neil MacLean; Rose Hurren; XiaoMing Wang; Feng-Hsu Lin; Jeff Wrana; Alessandro Datti; Dwayne L Barber; Mark D Minden; Malik Slassi; Aaron D Schimmer
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.